{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
Developments in the prescription drug market :
oversight : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fourteenth Congress, second session, February 4, 2016.
Developments In The Prescription Drug Market : Oversight : Hearing Before The Committee On Oversight And Government Reform, House Of Representatives, One Hundred Fourteenth Congress, Second Session, February 4, 2016.
United States.
U.S. Government Publishing Office,
2017.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
Examining issues related to competition in the pharmaceutical marketplace :
a review of the FTC report, Generic drug entry prior to patent expiration : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, October 9, 2002.
Examining Issues Related To Competition In The Pharmaceutical Marketplace : A Review Of The FTC Report, Generic Drug Entry Prior To Patent Expiration : Hearing Before The Subcommittee On Health Of The Committee On Energy And Commerce, House Of Representatives, One Hundred Seventh Congress, Second Session, October 9, 2002.
United States.
U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office],
2002.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
Examining issues related to competition in the pharmaceutical marketplace :
a review of the FTC report, Generic drug entry prior to patent expiration : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, October 9, 2002.
Examining Issues Related To Competition In The Pharmaceutical Marketplace : A Review Of The FTC Report, Generic Drug Entry Prior To Patent Expiration : Hearing Before The Subcommittee On Health Of The Committee On Energy And Commerce, House Of Representatives, One Hundred Seventh Congress, Second Session, October 9, 2002.
United States.
U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office],
2002.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
FDA and drug prices :
facilitating access to generic drugs
FDA And Drug Prices : Facilitating Access To Generic Drugs / Agata Dabrowska.
Bodie, Agata,
Congressional Research Service,
[2019]
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
FDA management and enforcement :
hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, September 12, 1991.
FDA Management And Enforcement : Hearing Before The Subcommittee On Oversight And Investigations Of The Committee On Energy And Commerce, House Of Representatives, One Hundred Second Congress, First Session, September 12, 1991.
United States.
U.S. G.P.O. : For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,
1992.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
FDA management and enforcement :
hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, September 12, 1991.
FDA Management And Enforcement : Hearing Before The Subcommittee On Oversight And Investigations Of The Committee On Energy And Commerce, House Of Representatives, One Hundred Second Congress, First Session, September 12, 1991.
United States.
U.S. Government Printing Office,
1992.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
Full committee hearing on Medicaid drug reimbursements :
are CMS cuts bad medicine for small businesses and beneficiaries?
Full Committee Hearing On Medicaid Drug Reimbursements : Are CMS Cuts Bad Medicine For Small Businesses And Beneficiaries? / Committee On Small Business, United States House Of Representatives.
United States.
U.S. G.P.O. : For sale by the Supt. of Docs., U.S. G.P.O.,
2007.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
Full committee hearing on Medicaid drug reimbursements :
are CMS cuts bad medicine for small businesses and beneficiaries?
Full Committee Hearing On Medicaid Drug Reimbursements : Are CMS Cuts Bad Medicine For Small Businesses And Beneficiaries? / Committee On Small Business, United States House Of Representatives.
United States.
U.S. Government Printing Office,
2007.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
Prioritizing public health :
the FDA's role in the generic drug marketplace : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Fourteenth Congress, second session : special hearing, September 21, 2016, Washington, DC.
Prioritizing Public Health : The FDA's Role In The Generic Drug Marketplace : Hearing Before A Subcommittee Of The Committee On Appropriations, United States Senate, One Hundred Fourteenth Congress, Second Session : Special Hearing, September 21, 2016, Washington, DC.
United States.
U.S. Government Publishing Office,
2017.
{{indexedTitle}} appears in the content of this record.
{{title}} can only be used in the library.
A copy of {{title}} has been set aside for library use only.
Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages :
hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012.
Review Of The Proposed Generic Drug And Biosimilars User Fees And Further Examination Of Drug Shortages : Hearing Before The Subcommittee On Health Of The Committee On Energy And Commerce, House Of Representatives, One Hundred Twelfth Congress, Second Session, February 9, 2012.
United States.
U.S. Government Printing Office,
2013.
